Overview of Alertec

Property	Description
Active ingredient	Modafinil
Form	Tablet (for oral administration)
Pharmacological class	Eugeroic Agent (Wakefulness-Promoting)
General purpose	Counteracting excessive daytime sleepiness
Origin	Synthetic compound

What Type of Medicine is Alertec and How is it Classified?

Alertec is a pharmaceutical product containing the active ingredient modafinil, a highly selective synthetic compound that is clinically recognized for its role in regulating alertness. The drug is classified as a Central Nervous System (CNS) stimulant but is uniquely distinguished as a eugeroic agent, which signifies its specialized action as a wakefulness-promoting agent. Unlike conventional psychostimulants, the profile of modafinil features an atypical mechanism that avoids the widespread systemic excitement seen with older stimulant classes. The ATC code for modafinil is N06BA07. Alertec is manufactured as a tablet for oral administration, defining its fundamental identity and form.

What is the General Purpose of a Eugeroic Agent?

The fundamental purpose of a eugeroic agent is to address and counteract severe or excessive daytime sleepiness by promoting a state of sustained wakefulness and attention. This mechanism is primarily utilized in scenarios where individuals experience profound drowsiness that interferes with their daily function. The targeted mechanism of effect involves selective influence on brain pathways, including the hypothalamic orexin (hypocretin) pathways and certain neurotransmitter pathways, distinguishing it as an agent focused specifically on enhancing alertness without broad cortical overstimulation. Modafinil's unique profile allows for the management of conditions characterized by profound sleepiness.

How Does Modafinil Relate to Armodafinil?

Modafinil is defined chemically as a racemic compound, meaning its structure is an equal mixture of two mirror-image forms known as the R- and S-enantiomers. The substance Armodafinil, which is marketed under a different trade name, represents a close chemical analogue in that it consists exclusively of the R-enantiomer, the longer-acting component of the two. This compositional difference is a key differentiator at the INN level, defining the precise molecular structure that influences the therapeutic properties of the tablets.

What side effects are possible with Alertec?

Possible side effects and safety information

The safety profile for Alertec (modafinil) is officially documented by regulatory authorities, with adverse reactions categorized by their frequency and the physiological system affected. The most frequently reported adverse reaction is headache, which is classified as very common (ge 1 in 10 patients) in official trial data.

Common Adverse Reactions

Reactions classified as common (ge 1 in 100 to le 1 in 10 patients) often involve the nervous system and gastrointestinal tract. These may include:

Nervous/Psychiatric Disorders: Insomnia, nervousness, anxiety, dizziness, somnolence, paraesthesia.
Gastrointestinal Disorders: Nausea, dry mouth, abdominal pain, diarrhoea, dyspepsia.
Cardiovascular Effects: Tachycardia, palpitation, and vasodilatation.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for rare, serious adverse events. These include life-threatening dermatological reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). The onset or worsening of psychiatric symptoms like mania, delusions, or suicidal ideation has also been documented.

Safety constraints and considerations are noted for specific populations. The use of the medication is generally not recommended in individuals with a history of left ventricular hypertrophy or mitral valve prolapse after prior CNS stimulant use. For females of reproductive potential, modafinil may reduce the effectiveness of hormonal contraceptives, requiring the use of alternative non-hormonal methods. Patients with severe hepatic impairment may require a dose reduction.

Overdose and Emergency Response

If an overdose of Alertec (modafinil) is suspected, immediate medical attention must be sought due to the documented potential for severe manifestations. Official regulatory documents describe a profile dominated by effects on the Central Nervous System (CNS) and the cardiovascular system.

Documented CNS manifestations include a cluster of symptoms indicative of excitation and agitation, such as insomnia, restlessness, disorientation, confusion, anxiety, and in severe cases, tremor and hallucinations. Cardiovascular symptoms frequently reported include significant changes in heart rhythm, specifically tachycardia (fast heartbeat) or bradycardia (slow heartbeat), along with hypertension (high blood pressure) and reported instances of chest pain. Gastrointestinal changes like nausea and diarrhea have also been noted.

Severe outcomes reported in regulatory post-marketing experience include the potential for cardiac arrhythmias, the onset of psychotic symptoms, and cases of fatal overdose when modafinil was taken alone or with other agents.

The mandated approach to managing an overdose is symptomatic and supportive treatment, as the prescribing information explicitly states that no specific antidote is known. Hospital monitoring may be required to manage these severe manifestations, and symptoms observed in pediatric cases are reported to be similar to those in adults.

Therapeutic Uses of Alertec

What Alertec Treats: Main Uses and Benefits

Alertec (modafinil) is applied for managing pathological and severe excessive daytime sleepiness (EDS), a condition characterized by symptoms of profound drowsiness. This medication is commonly used for managing the debilitating drowsiness associated with specific, diagnosed sleep-wake disorders. It is relevant for managing symptoms that interfere with daily functioning.

The medication is relevant for use in conditions presenting with significant symptomatic burden, including Narcolepsy, Shift Work Sleep Disorder (SWSD), and as an adjunct to primary treatment for residual sleepiness in Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS). The use of Alertec contributes to improved comfort during symptomatic periods by easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“The medication is relevant for managing symptoms that create noticeable functional strain and additional management of discomfort.”

Quick Fact: Relief for Excessive Sleepiness

Alertec may assist with supporting sustained wakefulness and vigilance during required waking hours, which is helpful in situations where symptoms of diminished alertness become temporarily overwhelming.

Regulatory References

NIH MedlinePlus overview on Modafinil

Eligibility and Restrictions for Use

This section outlines official eligibility and exclusion criteria for Alertec (modafinil) strictly based on government regulatory documentation. All use is limited to adults who meet specific clinical criteria.

Eligibility and Exclusion Criteria

Classification	Rule	Applicable Populations
Absolute Contraindication	Use is strictly prohibited.	Hypersensitivity to modafinil or armodafinil; documented Left Ventricular Hypertrophy (LVH); certain symptomatic Mitral Valve Prolapse; women who are pregnant or who may become pregnant (per international labels).
Age-Related Exclusion	Safety and effectiveness are not established.	Pediatric patients (under 17 or 18 years of age) due to the risk of severe skin reactions.
Conditional/Restricted Use	Requires dose reduction or special monitoring.	Patients with severe hepatic impairment (dose must be reduced to one-half); geriatric patients (lower doses and close monitoring advised); females of reproductive potential (must use effective non-hormonal contraception).

Regulatory Context

Regulatory agencies define strict constraints that limit its use. The medicine is not approved for use in children and is contraindicated for those with specific pre-existing heart conditions. Furthermore, female patients of childbearing age must comply with non-hormonal contraceptive requirements due to documented drug interaction that reduces the effectiveness of steroidal contraceptives.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope	Official Regulatory Information
Medicinal product categories with documented interactions:	Monoamine Oxidase Inhibitors (MAOIs), Steroidal Contraceptives, Anti-epileptic agents (e.g., Phenytoin, Carbamazepine), Anxiolytics (e.g., Diazepam), Immunosuppressants (e.g., Cyclosporine), and specific CYP enzyme substrates.
Mechanistic basis of interactions (only if stated in label):	Moderate Induction of CYP3A4/5 (Pharmacokinetic effect) leading to increased elimination of substrates. Reversible Inhibition of CYP2C19 (Pharmacokinetic effect) resulting in decreased clearance of substrates.
Timing-based interaction rules (if applicable):	Use of alternative or concomitant non-hormonal contraceptive methods is required during treatment and for two months after discontinuation. Co-administration with MAOIs is prohibited for 14 days after stopping the MAOI.
Population-specific interaction notes (if applicable):	Clearance may be reduced in the elderly and those with severe hepatic impairment, which can lead to increased systemic exposure of both modafinil and co-administered drugs.

Interaction Classifications (High-Level)

Interaction severity classification: Contraindicated Combinations (e.g., MAOIs, Mavacamten, Pacritinib); Clinically Significant Interactions requiring alternative measures (e.g., Steroidal Contraceptives); Exposure-Altering Interactions (CYP substrates).
Interaction-context constraints: The concurrent use of alcohol is advised against, as studies on co-administration are unavailable in official regulatory documents. Co-administration with food delays the rate of absorption but does not affect the total amount absorbed.

Resulting Interaction Structure

Official interaction statements:

Modafinil's role as a moderate inducer of CYP3A4/5 necessitates the use of effective non-hormonal contraception due to the documented risk of reduced effectiveness of steroidal contraceptives.
The inhibition of CYP2C19 by modafinil can lead to increased circulating levels of medicines primarily metabolized by this enzyme, such as certain anticonvulsants and anxiolytics.
The combination of modafinil with MAO Inhibitors is strictly prohibited due to the documented risk of acute pharmacodynamic effects.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define this drug's interaction structure primarily by its dual role as a metabolic modifier, increasing the clearance of certain drugs while decreasing the clearance of others via specific cytochrome P450 pathways. This dual activity mandates the use of alternative or concurrent measures for managing co-administered therapies. The profile includes absolute prohibitions and specific timing requirements detailed in official labeling.

Mechanism of Action

How Alertec Works: Mechanism of Action

Alertec (modafinil) operates through a dual pharmacodynamic mechanism that modulates central arousal circuits, primarily targeting specific neuronal systems in the brain. .

Modulating Dopamine and Preventing Reuptake

The mechanism involves the drug acting as a weak inhibitor of the Dopamine Transporter (DAT). This interaction blocks the reuptake of the monoamine neurotransmitter dopamine from the synaptic cleft into the presynaptic neuron. This action results in a subtle increase in extracellular dopamine concentrations. This alteration in monoamine levels is hypothesized to enhance signaling within pathways associated with cortical vigilance and executive function, contributing to the overall signaling profile in the central nervous system.

Activation of Orexin and Histamine Systems

A critical aspect of the mechanism is the drug's selective effect on hypothalamic neuronal systems that regulate arousal. Alertec activates the orexin/hypocretin neurons in the hypothalamus. This neural activation, in turn, stimulates the release of other endogenous arousal mediators, such as histamine. This targeted activation of the orexin-histamine cascade is a defining characteristic of the drug's mechanism, modulating central arousal and contributing to the characteristics of the resulting physiological state.

Dosage and Administration Information

How Alertec is Used: Official Administration and Dosing Principles

Alertec (modafinil) is an immediate-release tablet intended for oral administration. The medication is designed for continuous use, with the official administration principles centered on a once-daily dosing pattern to promote wakefulness during the necessary hours.

Standard Dosing Regimens

The most common adult dose for approved indications is 200 mg taken once daily. The dose is typically administered as a single tablet, though the full daily dose may be divided. The officially recognized maximum recommended dose is 400 mg per day.

Indication	Administration Timing
Narcolepsy & OSAHS	Take as a single dose in the morning.
Shift Work Sleep Disorder	Take approximately one hour prior to the start of the work shift.

Administration Conditions and Adjustments

The tablets may be taken with or without food. While food does not prevent absorption, taking the dose with a meal may slightly delay the time to peak concentration. If a dose is missed, standard practice is to skip the dose to prevent taking it too late, which could interfere with usual sleep patterns.

Specific dose modifications are required for certain populations. Patients with severe hepatic impairment are typically administered a reduced initial dose of 100 mg per day. Similarly, a lower starting dose, such as 100 mg, is advised when initiating treatment in older adults.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Alertec (Modafinil)

Evidence for Use in Excessive Daytime Sleepiness Associated with Narcolepsy

Research into Alertec (modafinil) was studied for excessive daytime sleepiness (EDS) related to narcolepsy in short-to-intermediate term Randomized Controlled Trials (RCTs). These studies involved adults diagnosed with narcolepsy, a condition marked by functional limitations due to sudden sleep episodes. Researchers examined objective measurements of sleep latency, such as standardized test scores that monitor wakefulness, as well as patient-reported outcomes. Studies report how symptoms evolved in the observed populations, describing patterns related to these measurements over the observation intervals. The consistency and weight of evidence for this indication was broadly categorized as High.

Evidence for Use in Excessive Daytime Sleepiness Associated with Shift Work Sleep Disorder (SWSD)

Alertec was studied for excessive sleepiness connected to Shift Work Sleep Disorder (SWSD). These trials involved short-to-intermediate term, placebo-controlled designs with adults who perform night or rotating shift work. The research examined measurements of sustained attention and objective wakefulness during periods when individuals typically experience sleepiness. The broad evidence level was categorized as Moderate to High.

What Research Gaps and Uncertainties Remain

The evidence highlights what is known—and what is still uncertain. A primary gap is the lack of extensive, long-duration research; the follow-up durations were limited in many key trials, making it difficult to fully characterize effects over many years. Therefore, long-term effects are not fully established, and this represents a significant research gap. Additionally, comparative evidence is lacking for how Alertec’s profile stacks up against other treatment approaches, and subgroup findings are uncertain for specific populations like children or those with various concurrent health issues.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Alertec (FAQ)

Q: Is Alertec available over-the-counter or does it need a prescription?

A: Alertec contains the active ingredient modafinil, which is classified as a prescription-only medicine. Official drug information confirms that it is not available for purchase without a valid prescription.

Q: How quickly does Alertec start to work after taking it?

A: Based on official pharmacokinetic studies, the drug is absorbed into the bloodstream. Peak concentrations in the blood are typically reached between two to four hours after the tablet is administered.

Q: What is the typical duration of action for a single dose of Alertec?

A: The effective elimination half-life of modafinil after multiple doses is described in regulatory documents as approximately 15 hours. This duration is primarily influenced by the R-enantiomer, which is the component responsible for the longer-lasting wakefulness effect.

Q: Can Alertec affect your ability to drive or operate machinery?

A: Official regulatory information describes a requirement for caution regarding driving or operating dangerous machinery. This is noted until it is known how the medication affects an individual's ability to perform these activities safely.

Q: Can Alertec be taken while breastfeeding?

A: Regulatory documents state that it is not known whether modafinil passes into human breast milk. Due to this uncertainty, regulatory information specifies that a healthcare provider should be consulted to determine appropriate options for feeding a baby if this medication is being used.

Q: Can Alertec be crushed or split if someone has trouble swallowing pills?

A: Official administration instructions describe that Alertec tablets are intended to be taken exactly as prescribed. Specific regulatory guidance on crushing or splitting the tablets is not typically provided in the product labeling. Unless alternative instruction is provided by a healthcare provider, the tablets are generally swallowed whole.

Q: What are the risks if too much Alertec is taken (overdose symptoms)?

A: Symptoms reported in cases of acute overdose have included nervousness, anxiety, confusion, insomnia, and palpitations. Other effects reported include a fast heart rate (tachycardia), tremor, nausea, and diarrhea. Severe cases may involve symptoms such as psychosis and hallucinations.

Q: Do official documents mention any potential for Alertec to be habit-forming?

A: The drug is classified as a Schedule IV controlled substance in the U.S. This classification is assigned based on the potential for abuse. Regulatory information notes that the medication may be habit-forming.

Q: Does Alertec have any known interactions with herbal supplements or vitamins?

A: Official documents describe the importance of notifying a healthcare provider of all products being used, including prescription and over-the-counter medicines, vitamins, and herbal supplements. This full disclosure allows the provider to evaluate the potential for all possible interactions with the medication.

Q: What does 'Altered Elimination' mean in the context of this drug?

A: 'Altered Elimination' is a technical term meaning the body removes the drug from the bloodstream more slowly than normal. This principle applies to certain patient groups, such as older adults, where reduced clearance may increase the levels of the medicine in the blood.

Q: Is there a mention of Alertec causing changes in appetite or weight?

A: Regulatory documents list both decreased appetite and increased appetite as uncommon side effects reported in clinical trials. Similarly, both weight decrease (weight loss) and weight increase have been reported as uncommon side effects.

Q: What is the main difference between Alertec and other allergy pills like it?

A: Alertec is officially classified as a wakefulness-promoting agent (eugeroic agent) that is used to treat conditions causing excessive sleepiness. The drug is not classified as an antihistamine, and its approved uses do not include the treatment of seasonal or other types of allergies.

Q: Is there a generic version of Alertec, and is it the same active ingredient?

A: Yes, Alertec is a brand name for the active ingredient modafinil. Modafinil is the generic name for the exact same chemical compound.

Q: Are there different strengths or forms (like liquid or tablets) of Alertec available?

A: Alertec (modafinil) is manufactured as an immediate-release tablet for oral use. According to regulatory labeling, the available strengths are typically 100 mg and 200 mg tablets.

Q: Are there known interactions between Alertec and common cold medicines?

A: Official sources warn against combining modafinil with other sympathomimetic agents, which is a class of drug often found in cold or decongestant medicines. The combination may increase the risk of certain side effects, such as elevated blood pressure and an increase in heart rate.

Q: Does Alertec interact with caffeine or energy drinks?

A: Both modafinil and caffeine affect the central nervous system, and official warnings note that combining them may increase the risk of certain side effects. These effects may include an impact on heart rate and blood pressure.

Q: Are people with kidney problems generally able to take Alertec?

A: Regulatory information primarily addresses dose adjustments for liver (hepatic) impairment, while specific guidelines for renal (kidney) impairment are generally not provided. Because there is a potential for slower removal of the drug in individuals with kidney issues, regulatory principles describe that its use requires evaluation by a physician.

Q: How Does Modafinil Relate to Armodafinil?

A: Modafinil is described as a racemic compound, meaning it contains both the R- and S-enantiomers. Armodafinil is a closely related medication that consists exclusively of the R-enantiomer, which is the component responsible for the medication's longer-lasting wakefulness effect.

How should Alertec be stored and disposed of?

How to Store and Dispose of Alertec?

The storage and disposal instructions for Alertec (modafinil) are defined by official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Alertec tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C, and kept from freezing or exposure to excess heat. The medication must be kept in a tightly closed container to protect it from moisture and direct light.

Safety and Disposal Rules

For safety, it is a mandatory requirement to keep Alertec out of the reach of children. Due to its classification as a controlled substance in certain regions, the medication should be stored in a secure location.

Disposal of unused Alertec must follow local governmental requirements. The official instruction is to discard expired or unused product through government-recommended drug take-back programs or authorized collection sites.

Alertec